This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Olive, C. Articles by Good, M. F. Search for Related Content PubMed PubMed Citation Articles by Olive, C. Articles by Good, M. F.

 Previous Article  |  Next Article 

Infection and Immunity, May 2003, p. 2373-2383, Vol. 71, No. 5
0019-9567/03/$08.00+0     DOI: 10.1128/IAI.71.5.2373-2383.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Potential of Lipid Core Peptide Technology as a Novel Self-Adjuvanting Vaccine Delivery System for Multiple Different Synthetic Peptide Immunogens

Colleen Olive,^1* Michael Batzloff,¹ Aniko Horváth,² Timothy Clair,¹ Penny Yarwood,¹ Istvan Toth,² and Michael F. Good¹

Cooperative Research Centre for Vaccine Technology, The Queensland Institute of Medical Research, Brisbane, Queensland 4029,¹ The School of Pharmacy, University of Queensland, Brisbane, Queensland 4067, Australia²

Received 29 October 2002/ Returned for modification 3 January 2003/ Accepted 28 January 2003

This study demonstrates the effectiveness of a novel self-adjuvanting vaccine delivery system for multiple different synthetic peptide immunogens by use of lipid core peptide (LCP) technology. An LCP formulation incorporating two different protective epitopes of the surface antiphagocytic M protein of group A streptococci (GAS)—the causative agents of rheumatic fever and subsequent rheumatic heart disease—was tested in a murine parenteral immunization and GAS challenge model. Mice were immunized with the LCP-GAS formulation, which contains an M protein amino-terminal type-specific peptide sequence (8830) in combination with a conserved non-host-cross-reactive carboxy-terminal C-region peptide sequence (J8) of the M protein. Our data demonstrated immunogenicity of the LCP-8830-J8 formulation in B10.BR mice when coadministered in complete Freund's adjuvant and in the absence of a conventional adjuvant. In both cases, immunization led to induction of high-titer GAS peptide-specific serum immunoglobulin G antibody responses and induction of highly opsonic antibodies that did not cross-react with human heart tissue proteins. Moreover, mice were completely protected from GAS infection when immunized with LCP-8830-J8 in the presence or absence of a conventional adjuvant. Mice were not protected, however, following immunization with an LCP formulation containing a control peptide from a Schistosoma sp. These data support the potential of LCP technology in the development of novel self-adjuvanting multi-antigen component vaccines and point to the potential application of this system in the development of human vaccines against infectious diseases.

---

* Corresponding author. Mailing address: Cooperative Research Centre for Vaccine Technology, Division of Infectious Diseases and Immunology, The Queensland Institute of Medical Research, P. O. Royal Brisbane Hospital, Brisbane, Queensland 4029, Australia. Phone: 61-7-3362 0431. Fax: 61-7-3362 0104. E-mail: colleenO{at}qimr.edu.au.

Editor: J. N. Weiser

---

Infection and Immunity, May 2003, p. 2373-2383, Vol. 71, No. 5
0019-9567/03/$08.00+0     DOI: 10.1128/IAI.71.5.2373-2383.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

This article has been cited by other articles:

• Staats, H. F., Alam, S. M., Scearce, R. M., Kirwan, S. M., Zhang, J. X., Gwinn, W. M., Haynes, B. F. (2007). In Vitro and In Vivo Characterization of Anthrax Anti-Protective Antigen and Anti-Lethal Factor Monoclonal Antibodies after Passive Transfer in a Mouse Lethal Toxin Challenge Model To Define Correlates of Immunity. Infect. Immun. 75: 5443-5452 [Abstract] [Full Text]